Understanding Your Treatment Options in BPDCN
How to Discuss Targeted Therapy with Your Doctor
Learn from the specialist who led the clinical trials for both approved targeted BPDCN treatments as he covers all you need to know about targeted therapy and how to talk to your doctor about your options.
Until recently, treating BPDCN (blastic plasmacytoid dendritic cell neoplasm, a rare blood cancer) meant relying on chemotherapy borrowed from other cancers. Now there are two FDA-approved targeted therapies, and the physician who led the clinical trials for both is sitting down to explain your options. Dr. Naveen Pemmaraju of UT MD Anderson Cancer Center joins patient advocate Andrew Schorr for a free, in-depth conversation built for patients and care partners navigating this disease right now.
Program Topics
- Learn what changed and why it matters: Two targeted therapies are now FDA-approved for BPDCN. Get a plain-language breakdown of how each one works and what the approval means for patients.
- Understand your treatment options side by side: Dr. Pemmaraju explains the difference between tagraxofusp (Elzonris) and pivekimab sunirine (Niktimvo), the side effects to know about, and how to work with your doctor on deciding the right approach for you.
- Know which questions to bring to your next appointment: From biomarker testing to stem cell transplant eligibility, learn what to ask your care team and when to ask it.
- Find out where the research is headed: Hear what combination approaches are showing promise in clinical trials now, and why trials are worth considering at every stage, not just at relapse.
Visit Our Partners
Thank you to Blood Cancer United for their partnership. They are here for you with information about clinical trials, resources, and dedicated support through their Information Specialists.
Program Sponsor
Thank you to our sponsor for its support of our independent patient education program. The Patient Story retains full editorial control over all content.